Oramed Initiates Food Effect Study for Its Oral Insulin Capsule ORMD-0801

NEW YORK, June 21, 2018 /PRNewswire/ — Oramed Pharmaceuticals Inc.(NASDAQ: ORMP) (TASE: ORMP) (www.oramed.com), a clinical-stage pharmaceutical company focused on the development of oral drug delivery systems, announced today that it has initiated a food effect study in the U.S. for its oral insulin capsule ORMD-0801. The food effect study is a single blind, five […]

Join our mailing list

Skip to content